Printed from the IBC Life Sciences Web site on July 2, 2016 3:23 AM ET.
Page location: http://www.ibclifesciences.com/26791.xml
To take place March 14-18, 2011 in Bellevue, WA
WESTBOROUGH, MA - December 7, 2011 - IBC Life Sciences is pleased to announce its annual Biopharmaceutical Development & Production week will take place March 14-18, 2011 at the Hyatt Regency in Bellevue, Washington. The week consists of six conferences covering unpublished data, case studies and panel discussions related to FDA guidelines, technology transfers, CMO relationships, antibodies, and next generation and novel molecules.
"The week is set up to allow for the greatest possible customization, offering attendees the ability to pick and choose the sessions they want to attend from the conferences," notes conference co-director Barry Walsh.
The week begins with three separate conferences on March 14-15: Process & Product Validation, Technology Transfer for Biopharmaceuticals, and Outsourcing Manufacturing of Biopharmaceuticals.
Then rounding out the week, IBC will host its flagship Antibody Development & Production conference on March 16-18 which will be held alongside the Recombinant Protein & Complex Biologics Development & Production and Analytical Technologies for Biotherapeutic Development conferences.
In addition, added to the agenda for 2011 is a half-day symposium that will take place on Tuesday afternoon, March 15 on "Novel Approaches for Viral Clearance/Validation".
The agenda features thirteen keynote speakers tackling the bioprocessing industry's current and future challenges, including three plenary presentations from the FDA/CDER on QbD, continuous verification and risk-based approaches to process understanding, as well as strategic discussions on "phase appropriate approaches to support exploratory IND" and "using continuous, disposable downstream processing to solve biomanufacturing's biggest problems."
Additional presentations will discuss improving speed, quality and cost of process development, implementing QbD, quality relations and lifecycle management, the future of biosimilars, optimizing manufacturing networks, maximizing recoverable titer, overcoming technical and scientific challenges of developing novel and next generation molecules, outsourcing strategies, external transfers, drug product validation and implementing novel analytical approaches and technologies to improve quality.
Attendees may choose to attend one conference or attend the full week with the all access pass. This event also includes two exhibit halls with over 60 biopharmaceutical supplier companies, open to all attendees.
Complete details on this event can be found at http://www.ibclifesciences.com/BDPWeek.
IBC Life Sciences is the worldwide leader in scientific, technological and business conferences and courses for the life science industry. For more information, visit www.IBCLifeSciences.com.